Statement from the Consumer Healthcare Products Association (CHPA) Regarding FDA Sunscreen Ingredient Maximal Usage Trial:

“The U.S. Food and Drug Administration (FDA) has been clear that sunscreens contribute substantial public health benefits and that Americans should continue to use currently marketed sunscreens confidently, and in their recent JAMA article, authors of FDA’s Maximal Usage Trial (MUsT) concluded by saying, ‘These results do not indicate that individuals should refrain from the use of sunscreen.’

“Sunscreen manufacturers, FDA, and dermatologists are aligned on the goal of protecting the public from the harmful effects of the sun. Sunscreens save lives and millions of Americans use these products on a daily basis to protect their health and the health of their families.”

“Previous FDA guidance has called for certain sunscreen active ingredients to undergo MUsT trials to assess absorption, and FDA also recently proposed a rule that would require more data on popular sunscreen ingredients to help ensure that they remain generally recognized as safe (GRAS). This MUsT data report is consistent with these efforts.



The Consumer Healthcare Products Association (CHPA) is the 138-year-old national trade association representing the leading manufacturers and marketers of over-the-counter (OTC) medicines and dietary supplements. Every dollar spent by consumers on OTC medicines saves the U.S. healthcare system more than $7, contributing a total of $146 billion in savings each year. CHPA is committed to empowering consumer self-care by preserving and expanding choice and availability of consumer healthcare products.  


Contact: Lauren Bloomberg (